- Home
- DGHI vs AVTX Comparison
DGHI vs AVTX Comparison
Compare DGHI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGHI
- AVTX
- Stock Information
- Founded
- DGHI 2017
- AVTX 2011
- Country
- DGHI United States
- AVTX United States
- Employees
- DGHI N/A
- AVTX N/A
- Industry
- DGHI Finance: Consumer Services
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- DGHI Finance
- AVTX Health Care
- Exchange
- DGHI Nasdaq
- AVTX Nasdaq
- Market Cap
- DGHI 90.1M
- AVTX 88.4M
- IPO Year
- DGHI N/A
- AVTX 2015
- Fundamental
- Price
- DGHI $1.95
- AVTX $8.44
- Analyst Decision
- DGHI Strong Buy
- AVTX Strong Buy
- Analyst Count
- DGHI 1
- AVTX 4
- Target Price
- DGHI $2.50
- AVTX $33.00
- AVG Volume (30 Days)
- DGHI 975.9K
- AVTX 37.8K
- Earning Date
- DGHI 04-02-2025
- AVTX 03-28-2025
- Dividend Yield
- DGHI N/A
- AVTX N/A
- EPS Growth
- DGHI N/A
- AVTX N/A
- EPS
- DGHI N/A
- AVTX N/A
- Revenue
- DGHI $42,146,057.00
- AVTX $820,000.00
- Revenue This Year
- DGHI N/A
- AVTX N/A
- Revenue Next Year
- DGHI N/A
- AVTX N/A
- P/E Ratio
- DGHI N/A
- AVTX N/A
- Revenue Growth
- DGHI 100.56
- AVTX N/A
- 52 Week Low
- DGHI $0.84
- AVTX $4.24
- 52 Week High
- DGHI $3.77
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- DGHI 37.60
- AVTX 57.77
- Support Level
- DGHI $2.81
- AVTX $6.81
- Resistance Level
- DGHI $3.48
- AVTX $8.00
- Average True Range (ATR)
- DGHI 0.35
- AVTX 0.56
- MACD
- DGHI -0.15
- AVTX 0.03
- Stochastic Oscillator
- DGHI 4.12
- AVTX 81.99
About DGHI Digihost Technology Inc. Common Subordinate Voting Shares
Digihost Technology Inc is a blockchain company focused on Bitcoin mining. The company's mining facility is located in Buffalo, New York, and is equipped with an 18.7 MVA 115,000-kilovolt ampere outdoor substation with an option to increase the power output to 42MVA.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).